Dyadic International, Inc.

Equities

DYAI

US26745T1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.65 ^USD	-0.60%		+13.80%	+2.48%

May. 14	Transcript : Dyadic International, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14	Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q1 Revenue $334.6M	MT

Dyadic International, Inc. Announces Executive Changes, Effective August 4, 2014

July 30, 2014 at 08:30 am EDT

Dyadic International, Inc. announced the appointment of Thomas Tom Dubinski as Vice President and Chief Financial Officer. Tom will be responsible for leading the financial and information technology operations for Dyadic and will succeed Michael Faby effective August 4, 2014. Prior to joining Dyadic, Tom held senior management positions at Fortune 500 businesses with global operations.

From 2012 to 2014, Tom served as a management consultant at CFO Solutions.

Latest news about Dyadic International, Inc.

Transcript : Dyadic International, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q1 Revenue $334.6M	May. 14	MT
Transcript : Dyadic International, Inc., 2023 Earnings Call, Mar 28, 2024	Mar. 28
Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Dyadic Says Patrick Lucy Named Board Chair; Joseph Hazelton Appointed COO	Mar. 28	MT
Dyadic International, Inc. Announces Management Changes	Mar. 28	CI
Dyadic International, Inc. announced that it has received $6 million in funding	Mar. 07	CI
Dyadic International, Rabian Collaborate to Develop Rabies Vaccine	Feb. 28	MT
Dyadic Advances Collaboration with Israel Institute for Biological Research Targeting Bio-Threats and Emerging Disease Solutions	Feb. 21	CI
Dyadic International Partners With Maravai LifeSciences' Cygnus Technologies Unit on HCP Assay	Feb. 13	MT
Dyadic International Inc. and Cygnus Technologies Announce Partnership to Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing	Feb. 13	CI
Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate	Nov. 29	CI
Dyadic International Says C1 Platform Chosen for Vaccine Production in Africa	Nov. 20	MT
Dyadic International, Inc. Announces its C1 Platform to Be Use to Produce Vaccines for Humans and Animals in Africa	Nov. 20	CI
Transcript : Dyadic International, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Dyadic International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Janssen Biotech, Inc. Terminates Research, License, and Collaboration Agreement with Dyadic International, Inc	23-10-06	CI
Dyadic International, Inc. Enters into Research Collaboration Agreement with Voltron Therapeutics, Inc	23-10-05	CI
Dyadic International, Inc. and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells	23-09-26	CI
Dyadic International, Inc. Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus?	23-09-19	CI
Transcript : Dyadic International, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Dyadic International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q2 Revenue $837,159, vs. Street Est of $1.3M	23-08-09	MT
Dyadic Announces Positive Results from Third Party Analytical Testing of Animal-Free Recombinant Serum Albumin	23-08-07	CI
Dyadic International, Inc Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate	23-07-24	CI

Chart Dyadic International, Inc.

Duration

Period

More charts

Company Profile

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - Lytham Spring Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Dyadic International, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.65 USD

Average target price

7.5 USD

Spread / Average Target

+354.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DYADIC INTERNATIONAL, INC.	+2.48%	48.24M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research